Oxford Biodynamics (OBD) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Oct 2017 07:00 AM
RNS
Presents at the Diabetes Asia 2017 Conference
11 Oct 2017 07:00 AM
RNS
Presents ALS signatures at NEALS
03 Oct 2017 07:00 AM
RNS
Announces grant of US patent for EpiSwitchT
28 Sep 2017 07:00 AM
RNS
Successful in diagnosing and staging breast cancer
15 Sep 2017 07:00 AM
RNS
Directorate Update
30 Jun 2017 07:00 AM
RNS
Appointment of Paul Stockdale as CFO
13 Jun 2017 07:00 AM
RNS
Targets Amyotrophic Lateral Sclerosis in Asia
13 Jun 2017 07:00 AM
RNS
Interim Results
31 May 2017 07:00 AM
RNS
Notice of Interim Results
31 May 2017 07:00 AM
RNS
Publication highlights advantages of EpiSwitchT
23 May 2017 07:00 AM
RNS
Development Agreements with Top Pharma Companies
19 May 2017 07:00 AM
RNS
Appointment of Shore Capital as Joint Broker
18 May 2017 07:00 AM
RNS
Subsidiary signs exclusive Asia licence
20 Apr 2017 07:00 AM
RNS
Representation on NIH steering committees
17 Mar 2017 07:00 AM
RNS
BIO-FLARE Collaboration
15 Mar 2017 03:18 PM
RNS
AGM Results and Related Party Transaction
09 Mar 2017 07:00 AM
RNS
Appointment of Martin Reeves as SVP
13 Feb 2017 07:00 AM
RNS
Appointment of Dr Claudio Carini
31 Jan 2017 07:00 AM
RNS
Final Results
23 Jan 2017 07:00 AM
RNS
Pilot project with EpiFit
13 Jan 2017 04:24 PM
RNS
Notice of Results
09 Dec 2016 10:04 AM
RNS
Holding(s) in Company
08 Dec 2016 09:44 AM
RNS
Holding(s) in Company
08 Dec 2016 09:42 AM
RNS
Holding(s) in Company
08 Dec 2016 09:41 AM
RNS
Holding(s) in Company
08 Dec 2016 09:39 AM
RNS
Holding(s) in Company
08 Dec 2016 09:34 AM
RNS
Holding(s) in Company
08 Dec 2016 09:31 AM
RNS
Holding(s) in Company
08 Dec 2016 09:29 AM
RNS
Holding(s) in Company
06 Dec 2016 07:00 AM
RNS
Admission to AIM and First Day of Dealings

Oxford Biodynamics' international store for clinical smart tests and research kits based on pioneering EpiSwitch® 3D genomic technology.

OBD was spun out of Oxford University in 2007 to commercialize blood tests based on 3D Genomics research. OBD's tests are designed to help people make informed health decisions and reduce healthcare costs.

OBD share price launched at 162p in 2016.

UK 100

Latest directors dealings